BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 26, 2007
View Archived Issues
Six-month study shows prevention of depressive relapses with agomelatine
Read More
Recent Atir patent discloses novel agents for male sexual dysfunction
Read More
Novel antiinfectious agent reported in recent patent literature
Read More
Recent patents report novel therapeutic agents for neurological disorders
Read More
AST-120 effective in pouchitis pilot study
Read More
MBP-8298 safe in phase III MAESTRO-01 multiple sclerosis trial
Read More
Minocycline beneficial in patients with acute stroke
Read More
Aida identifies potential targets in phase II trial with Rh-Apo2L
Read More
Dynavax starts environmental exposure chamber study of Tolamba
Read More
DepoDur modified-release injection approved in Australia
Read More
Aripiprazole ineffective in treating methamphetamine dependence
Read More
Avant and Celldex sign merger and provide update on future activity
Read More
Raptor establishes subsidiary and acquires first clinical-stage product
Read More
Kyowa Hakko and Kirin Pharma to merge
Read More
Can-Fite's CF-102 promotes liver tissue regeneration following partial hepatectomy
Read More
FDA and EMEA grant orphan drug status to SQ-109 for tuberculosis
Read More
Summit initiates phase I clinical trial of SMT-D002 for seborrhea in PD
Read More
Mutations in PEX2 identified as the cause of Zellweger syndrome
Read More
Dendreon completes enrollment in phase III trial of Provenge for advanced prostate cancer
Read More
Lu-AA-24530 enters phase II for mood and anxiety disorders
Read More
Oncolytics Biotech receives U.K. approval to evaluate Reolysin
Read More
Morria Biopharmaceuticals advances MRX-4 to phase I for allergic rhinitis
Read More
PAION commences phase I trial of Solulin
Read More
APITD1, a candidate tumor suppressor gene in neuroblastoma
Read More
Inhibitex begins phase I study of FV-100 for shingles
Read More
FDA accepts Wyeth's sNDA for Tygacil in CAP
Read More
FDA grants fast track designation to Phamasset's R-7128 in chronic HCV
Read More